Lu-177-Labeled Macroaggregated Albumin Imaging and Treatment Effect in Patient with Cystic Thyroid Nodule

SAğER M. S., AYGÜN A., KARAYEL E., Pehlivanoglu H., SÖNMEZOĞLU K.

JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, cilt.48, sa.1, ss.79-80, 2020 (ESCI, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 48 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2967/jnmt.119.226340
  • Dergi Adı: JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Agricultural & Environmental Science Database, Biotechnology Research Abstracts, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.79-80
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

A number of different peptides or antibodies have been labeled with Lu-177 and used for clinical imaging and treatment. To our knowledge, Lu-177 had never before been used to label macroaggregated albumin, and our radiopharmacy laboratory at Istanbul University-Cerrahpasa made a special effort to do so. We present the case of a 43-y-old man whose cystic thyroid nodule was treated with an intranodular injection of Lu-177-macroaggregated albumin and imaged with SPECT/CT.